Invention Grant
- Patent Title: Ii-key/antigenic epitope hybrid peptide vaccines
- Patent Title (中): Ii-key /抗原表位杂交肽疫苗
-
Application No.: US12843466Application Date: 2010-07-26
-
Publication No.: US08815249B2Publication Date: 2014-08-26
- Inventor: Robert Humphreys , Minzhen Xu
- Applicant: Robert Humphreys , Minzhen Xu
- Applicant Address: US MA Worcester
- Assignee: Antigen Express, Inc.
- Current Assignee: Antigen Express, Inc.
- Current Assignee Address: US MA Worcester
- Agency: Pierce Atwood LLP
- Agent Kevin M. Farrell; David J. Wilson
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/385 ; A61K39/145 ; A61K48/00 ; A61K38/04

Abstract:
Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope, or said encoded protein or peptide. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide, or said encoded protein or peptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.
Public/Granted literature
- US20100291145A1 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES Public/Granted day:2010-11-18
Information query